Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.49 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11980119 | 0.87 | GAA (0.50) | GAAGRIN2BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL20760976 | 0.81 | GRIN2B (0.59) | GAAGRIN2BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL14161697 | 0.80 | GRIN2B (0.76) | GAAGRIN2BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL25364252 | 0.77 | NOTUM (0.47) | L3MBTL1MBTD1L3MBTL3CYP2C9 | |
| SCHEMBL13240777 | 0.76 | GRIN2B (0.65) | GAAGRIN2BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL737747 | 0.76 | GRIN2B (0.65) | GAAGRIN2BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL11980117 | 0.76 | GRIN2B (0.65) | GAAGRIN2BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL21410680 | 0.76 | BPTF (0.42) | ALDH1A1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL25260 | 0.76 | GRIN2B (0.65) | GAAGRIN2BALDH1A1MAPTL3MBTL1 | |
| SCHEMBL20503412 | 0.75 | KDM4E (0.39) | GAAALDH1A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695449-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-10695449-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190054198-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2019-02-21 | — | — | US | disclosed |
| US-20190054198-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION | 2019-02-21 | — | — | US | disclosed |
| US-10098974-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-16 | — | — | US | disclosed |
| US-10058625-B2 | Catalytic radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2018-08-28 | — | — | US | disclosed |
| US-20150283273-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2015-10-08 | — | — | US | disclosed |
| US-20150283273-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2015-10-08 | — | — | US | disclosed |
| US-20150283273-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2015-10-08 | — | — | US | disclosed |
| US-20150132223-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION | 2015-05-14 | — | — | US | disclosed |
| US-20100215578-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-20100215578-A1 | Catalytic Radiofluorination | THE GENERAL HOSPITAL CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-7632485-B2 | Catalytic radiofluorination | MASSACHUSETTS GENERAL HOSPITAL (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632485-B2 | Catalytic radiofluorination | MASSACHUSETTS GENERAL HOSPITAL (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1725269-A4 | CATALYTIC RADIOFLUORINATION | GEN HOSPITAL CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008022319-A2 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| CN-1921893-A | Catalytic radiofluorination | GEN HOSPITAL CORP (US) | 2007-02-28 | — | — | CN | disclosed |
| EP-1725269-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2006-11-29 | — | — | EP | disclosed |
| US-20050260130-A1 | Arylphosphonium compounds containing fluorine-18 that are useful as imaging agents; in particular, the phosphonium compound is a tetraaryl phosphonium salt, [F-18]-(4-fluorophenyl)triphenylphosphonium nitrate; Position Emission Tomography | MASSACHUSETTS GENERAL HOSPITAL (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005082425-A1 | CATALYTIC RADIOFLUORINATION | THE GENERAL HOSPITAL CORPORATION (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098974-B2 | Catalytic radiofluorination | ARSA, STS, KCNK18 | GAA 490/4885GRIN2B 4059/4885ALDH1A1 1308/4885 |
| US-10058625-B2 | Catalytic radiofluorination | KCNJ5, KCNQ5, KCNK18 | GAA 1603/4885GRIN2B 4487/4885ALDH1A1 1427/4885 |
| US-20190054198-A1 | CATALYTIC RADIOFLUORINATION | KCNJ5, KCNQ5, KCNK18 | GAA 1603/4885GRIN2B 4487/4885ALDH1A1 1427/4885 |
| US-20050260130-A1 | Arylphosphonium compounds containing fluorine-18 that are useful as imaging agents; in particular, the phosphonium compound is a tetraaryl phosphonium salt, [F-18]-(4-fluorophenyl)triphenylphosphonium nitrate; Position Emission Tomography | KCNK18, KCNJ5, KCNQ5 | GAA 4657/4885GRIN2B 3399/4885ALDH1A1 3071/4885 |
| US-20150283273-A1 | Catalytic Radiofluorination | KCNJ5, KCNQ5, KCNK18 | GAA 1603/4885GRIN2B 4487/4885ALDH1A1 1427/4885 |
| US-10695449-B2 | Catalytic radiofluorination | KCNJ5, KCNQ5, KCNK18 | GAA 1603/4885GRIN2B 4487/4885ALDH1A1 1427/4885 |
| US-20100215578-A1 | Catalytic Radiofluorination | KCNJ5, KCNQ5, KCNK18 | GAA 1603/4885GRIN2B 4487/4885ALDH1A1 1427/4885 |
| US-20150132223-A1 | Catalytic Radiofluorination | ARSA, KCNK18, STS | GAA 590/4885GRIN2B 3857/4885ALDH1A1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.